chrisvoncsefalvay/vaers-outcomes huggingface dataset:
I Can't talk/without a voice; pain in both legs; hard to walk; This case was received via an unknown source (no reference has been entered for a health authority or license partner) on 28-Jun-2021 and was forwarded to Moderna on 28-Jun-2021.    This spontaneous case was reported by a consumer and describes the occurrence of APHASIA (I Can't talk/without a voice), PAIN IN EXTREMITY (pain in both legs) and GAIT DISTURBANCE (hard to walk) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced APHASIA (I Can't talk/without a voice), PAIN IN EXTREMITY (pain in both legs) and GAIT DISTURBANCE (hard to walk). At the time of the report, APHASIA (I Can't talk/without a voice), PAIN IN EXTREMITY (pain in both legs) and GAIT DISTURBANCE (hard to walk) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No relevant concomitant medications were provided.  No treatment information was provided.
Side effect from 1dose of Pfizer, I get Chills,Muscle Pain, Headache's,Nausea,legs and feet Swelling, Vomiting, Have to take a aspirin to stop the filling every 3 hours or so...
FATIGUE, NAUSEA, VOMITING, RASH, WEAK, LOW GRADE FEVER, CHILLS, SWEATS. SEEN ON 05/07/12 BY DR. Skin: Diffuse maculo-papular erythematous almost purple in spots rash across arms trunk and legs. CLASSIC DRUG LIKE RASH. RX PREDNISONE AND BENADRYL.
Long-term dizziness and lightheadedness  Increasing frequency of passing out and seizing in heat and elevation gain (once a month in January after vaccine, now twice in a week)  I passed out and got a concussion after my second dose in February, for example...
This case was considered medically important. Information regarding PREVNAR was received from a healthcare professional regarding a 6-month-old female patient who became pale, unconsciousness, cyanotic around mouth, went limp and experienced unconsciousness. The patient received a dose on 18-Jan-2010. The patient also received a dose of HIB (manufacturer unknown) on 18-Jan-2010. After being administered the PREVNAR and the HIB on 18-Jan-2010, the patient became pale and cyanotic around mouth. She went limp and experienced unconsciousness. These events lasted about 30 seconds to 1 minute and then the patient returned to "normal". Another unspecified vaccine was administered but then the physician suggested that all other immunization to be withheld. No additional information was available at the time of this report.
fever 102.8 p/vax 15MAY98;mom reported a rash p/2mo shots 7JUL98 w/non-stop crying @ that time;mom consented to HIB/HBV & OPV 15MAY98 & rash, fever, irritable behavior;
This case was reported by a consumer and described the occurrence of visual impairment in a 38 yr old female subject who was vaccinated with hep A inactivated and hep B recombinant vaccine (Twinrix) for prophylaxis. A physician or other health care professional has not verified this report. The subject has a history of allergy to cranberries and erythromycin. No additional medical history or concurrent conditions were provided. Concurrent medications included birth control. On 29Jun06 at 08:40 the subject received unspecified dose number of Twinrix (lot number and expiration date were not provided) at 1ml, IM to the left arm. Two hours and 20 mins later, the subject developed impaired vision and painful hives. Seven hours later, the subject experienced trouble breathing. A full day and 14 hrs later, on 01Jul06, (08:00), the subject was unable to walk. This case was assessed as medically serious by manf (OMIC). All events with the exception of impaired vision, resolved by 02Jul06. The subject's vision had not yet returned to normal at the time of reporting.
Monitoring post COVID-19 booster vaccination, resident had a seizure at 1130 lasting 45 seconds. Resident was in w/c and started shaking tensed up and held his breath, staff gave resident a sternal rub and he started taking in deep breaths. After about two minutes resident breathing normalized and vitals stable 132/80, 78, 97.5, 15, 97ra.
Heaviness in left foot and calf, Drs ruled out blood clot. Continuing with numbness and pain/ heaviness . Neurologist ordered more labs.
RECIPIENT RECEIVED BIVALENT PFIZER BOOSTER IN OCTOBER 2022 AND RECEIVED ANOTHER ONE ON 1.5.23
Shingles like Rash that slowly, over two days appeared but bit by bit, extending  from vaccination site.  Went about four inches down arm and is about 3 inches wide.  It is 3 days now and almost gone, but it is leaving bit by bit in order or arrival.  It is not hives as it hurts to touch and muscle under rash hurts to touch as well.  vaccination site had about a nickel size swollen red area but this  went away and muscle under vaccination site no longer hurts.
Severe body and muscle aches, severe stomach cramping, chills, fatigue, inability to sleep, vomiting. Began Wednesday late night, about 11:30 PM, and lasted for a little more than 36 hours. Muscle cramping in legs continues to date, which is January 25, 2022.
Pt was vaccinated in the left deltoid at 0851. At 0853, while standing and waiting for sister to be vaccinated, pt passed out and hit her head. Patient was carried to the gurney and an MD STAT was called at 0855. MD STAT team arrived at 0856 and Pediatrician took point of care. T: 98.3 HR 89  BP 98/48 (64)  SAT 100. Patient pale but alert and oriented. The doctor transferred her to treatment room at 0905.
Breakthrough case admission after three vaccines: Pfizer 3/23/2021 batch/lot# ER8727; Pfizer 4/13/2021 batch/lot#  ER8732; Pfizer 12/28/2021 batch/lot# FL3198.
On the same day of COVID vaccine patient received her Immune globulin injection that she receives monthly (refer to med list). March 29th 2021- patient started having decreased strength and coordination in hands.  March 31st 2021- patient was very sleepy and slept over 24 hours April 1st 2021- Could not feed herself and was very uncoordinated with her hands/arms.
Painful lump appeared at vaccine site the day following vaccine administration. Black bruising began and spread. As of 9/8/16, lump exists but has subsided and black and red bruising. Pt says it still hurts upon touch. Advised pt to consult physician.
This spontaneous report has been received from a physician referring to a patient of unknown age and gender. On an unknown date the patient was vaccinated with one dose of PNEUMOVAX 23 (lot # and dose not reported). On an unknown date (one year after the first dose of PNEUMOVAX 23), the patient received the second dose of PNEUMOVAX 23 (lot # and dose not reported). Then on an unknown date, the patient experienced swelling at injection site and overall swelling in the arm that the second dose of vaccine was administered. The patient was treated with unspecified steroids on unspecified date. At the time of report, the patient had been fully recovered. This is one of several reports received from the same source. Additional information is not expected because the reporter did not want to be contacted.
On 9/30, agency was notified by an out-of-state health services company that a nurse had reused syringes for multiple persons either that day at an employee influenza vaccination clinic where the health services company had been contracted. The nurse contracted by the health services company brought three multiple-dose vials of vaccine that were intended for another event (and stored in her personal fridge without temp monitoring). The nurse reported using two syringes she found among her supplies to administer vaccine to 67 employees of the business. She reported wiping the syringes with alcohol and using a new needle for each of the 67 persons. Only 2 multiple dose vials of vaccine (10 doses/vial) were used for 67 adult participants. Participants were offended bloodborne pathogen testing (hep B, hep C, HIV), hepatitis B vaccine, and flu vaccine.
memory loss; "fuzzy brain"; "brain fog"; "having difficulty remembering names"; "brain is racing at night"; having trouble sleeping; anxiety; headache; soreness in the left arm; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (soreness in the left arm), HEADACHE (headache), AMNESIA (memory loss), CONFUSIONAL STATE ("fuzzy brain") and FEELING ABNORMAL ("brain fog") in a 66-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 030H20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     The patient's past medical history included No adverse event. Concomitant products included PRAVASTATIN and MULTIVITAMINS & MINERALS PLUS LUTEIN for an unknown indication.    On 25-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 25-Feb-2021, the patient experienced PAIN IN EXTREMITY (soreness in the left arm). On 26-Feb-2021, the patient experienced HEADACHE (headache). On an unknown date, the patient experienced AMNESIA (memory loss), CONFUSIONAL STATE ("fuzzy brain"), FEELING ABNORMAL ("brain fog"), APHASIA ("having difficulty remembering names"), ANXIETY ("brain is racing at night"), INSOMNIA (having trouble sleeping) and ANXIETY (anxiety). On 27-Feb-2021, PAIN IN EXTREMITY (soreness in the left arm) had resolved. At the time of the report, HEADACHE (headache), AMNESIA (memory loss), CONFUSIONAL STATE ("fuzzy brain"), FEELING ABNORMAL ("brain fog"), APHASIA ("having difficulty remembering names") and ANXIETY ("brain is racing at night") had resolved and INSOMNIA (having trouble sleeping) and ANXIETY (anxiety) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.
Discharge Diagnosis:  Hypoxia, COVID 19, Elevated d.dimer, Elevated tropoin,. Dm2, HTN.    Hospital Course:  The patient was admitted with elevated troponin and covid PNA. She was hypoxic very shortly on admission but was off oxygen for over 48 hours prior to discahrge. She was seen by cardiology who felt that her troponin was due to covid 19 and not ACS. She had a preserved EF on 2D echo. She got 3 days of remdesevir while here and was doing well off oxygen.
Patient was given expired (shortdated) vaccine; This spontaneous case was reported by a nurse and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Patient was given expired (shortdated) vaccine) in a 38-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 003F21A) for COVID-19 vaccination.     No Medical History information was reported.    On 30-Aug-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 30-Aug-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (Patient was given expired (shortdated) vaccine). On 30-Aug-2021, EXPIRED PRODUCT ADMINISTERED (Patient was given expired (shortdated) vaccine) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medication were provided by the reporter  No treatment medication were provided by the reporter
This spontaneous report as received from two pharmacists (one via field representative) refers to a patient of unknown age. On 24-OCT-2013 the patient was vaccinated with ZOSTAVAX vials of lot number J006156 and expiry date 30-AUG-2014. Dose and route were unspecified. The reporter informed that a shipment (referred as second) of improperly stored ZOSTAVAX vials (lot number J006156 and expiry date 30-AUG-2014) received on 11-OCT-2013 were exposed to 5 degrees centigrade for approximately 41 days. The patient had been administered with the improperly stored vaccine. No adverse event was reported. This is 13 of several reports from same reporter. Additional information has been requested.
This case was reported by a other health professional via call center representative and described the occurrence of inappropriate age at vaccine administration in a 2-year-old unk patient who received FLUARIX QUADRIVALENT (batch number 3227Z, expiry date 30th June 2015). On 6th January 2015, the patient received FLUARIX QUADRIVALENT .5 ml. On an unknown date, the dose was an unknown dose. On an unknown date, an unknown time after receiving FLUARIX QUADRIVALENT, the patient experienced inappropriate age at vaccine administration. On an unknown date, the outcome of the inappropriate age at vaccine administration was unknown. Additional information received: FLUARIX QIV mistakenly administered to a 2yo (full 0.5 ml dose) instead of a pediatric flu vaccine that is approved for this age group.
2nd dose was administered 1 week early: patient received initial dose on 2/13/2021- vaccination card had return date of 3/13/2021 for 2nd dose.    3/6/2021 @ 1212: pt was called, no answer, LMOR. 3/6/2021 @ 1551: pt states injection was exactly 4 weeks ago, pt is doing well without any reported side effects; it was discussed that there is no recommendation for a 3rd dose.
Myalgia & Arthralgia Narrative:  fatigue and body aches, unable to work on  2/10 due to symptoms
Patient was administered FLUZONE QUAD at approximately 2:30 on 8/30/17 in her left arm. She did not experience any pain upon administration. Later that night at approximately 6:30 pm she began having arm pain upon moving her arm. She took ibuprofen days after receiving the vaccination and did not experience relief. She also received a course of prednisone and this still did not alleviate the pain. She has been experience left arm pain a month after initially receiving the vaccination.
Body feels heavy; Feels as if cold is coming; Aching; Headache; This spontaneous case was reported by a consumer and describes the occurrence of DISCOMFORT (Body feels heavy), NASOPHARYNGITIS (Feels as if cold is coming), HEADACHE (Headache) and MYALGIA (Aching) in an 83-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 027C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 12-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 12-May-2021, the patient experienced HEADACHE (Headache). On 13-May-2021, the patient experienced DISCOMFORT (Body feels heavy), NASOPHARYNGITIS (Feels as if cold is coming) and MYALGIA (Aching). At the time of the report, DISCOMFORT (Body feels heavy), NASOPHARYNGITIS (Feels as if cold is coming), HEADACHE (Headache) and MYALGIA (Aching) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications were reported  No treatment drugs were reported
Sore arm; This is a spontaneous report from a contactable consumer. A female patient of an unspecified age received first dose of bnt162b2 (Pfizer COVID-19 Vaccine: Solution for injection; Batch/Lot number was not reported), dose 1 via an unspecified route of administration on 10Feb2021 as dose 1, single for COVID-19 immunisation. The patient medical history and concomitant medications were not reported. On 10Feb2021 patient experienced sore arm; she has not had any problem other than a sore arm since the Pfizer COVID-19 Vaccine. When she got the Pfizer COVID-19 Vaccine she was given a lot of information. The paperwork she was given said she should have the second dose of Pfizer COVID-19 Vaccine 3 weeks after the first dose. She is scheduled for the second dose of Pfizer COVID-19 Vaccine 4 weeks and 2 days after the first dose was administered. She is concerned about whether that 4 weeks and 2 days period is too long between doses; if it is ok to get the second dose that long after the first dose. The outcome of the event was unknown.  information about lot/batch number requested.  Follow-up attempts are completed. No further information is expected.
On 28FEB92 pt recvd DTP & about 10 hrs later t105 ax o other sx x/fever; yellow-green mucus & early rt OM; fever poss due to upper resp infection;
got covid; got covid; really sick; This is a spontaneous report from a Pfizer-sponsored program,  from a contactable consumer. This consumer reported similar events for two patients. This is the second of two reports.   An 83-year-old female patient received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, lot number and expiration date not provided) via an unspecified route of administration on an unspecified date as a single dose for COVID-19 immunisation. The patient's medical history and concomitant medications were not reported. The reporter (patient's daughter) stated that the patient received her first dose on 07Mar2021 and got COVID on an unspecified date. She wanted to know when the patient can get the second dose. She said the patient have COVID-19 on an unspecified date and was really sick and have been under quarantine for the last 11 days now. She wanted to know how long after the patient was well can she get the second dose and also, if she can still get it. The outcome of the events was unknown.   No follow-up attempts are possible; information about lot/batch number cannot be obtained.; Sender's Comments: Linked Report(s) : US-PFIZER INC-2021335963 same reporter, drug/event, different patient
This spontaneous report was received from a registered nurse refers to a 5 years old female patient who on 08-AUG-2012, was vaccinated subcutaneously with 0.65 ml dose of ZOSTAVAX (lot number not reported) instead of VARIVAX (Merck). No other co-suspects were reported. Concomitant vaccines included KINRIX and MMR II administered during the same office visit on 08-AUG-2012. The registered nurse reported that on 08-AUG-2012, the patient demonstrated injection site pain, as evidence by"I could hear her screaming down the hall". No treatment was given for the experience. At the time of the report, the registered nurse stated that the patient was stable. It was unspecified if the patient sought medical attention. The relatedness for the patient demonstrated injection pain was unknown for ZOSTAVAX. Additional information has been requested.
severe chest pain, unrelieved by any over the counter medication, continued throughout night. then chest pain continued to happened intermittently for months
Start: lazy eye (right side) Next day:  itchy, swollen eye (right side) Yesterday:  Irritation, swelling itchy eye (right side) Today:  right eye, swollen, Lips swollen
SM develops HA, malaise, arthralgias, myalgias, fatigue after AVA and recurs with each successive vaccine.
developed swelling in the cheek and under the eye; developed swelling in the cheek and under the eye; rash; Little lightheaded; This is a spontaneous report received from a contactable consumer (reporting on herself). A 72-years-old female patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Formulation: Solution for injection, Lot Number: EM9810; Expiration Date: Jun2021) via an unspecified route of administration in Arm Left on 08Feb2021 09:30 as single dose for COVID-19 immunization. Medical history included food allergy, arthropod sting, drug hypersensitivity, hypersensitivity. There were no concomitant medications. On 08Feb2021 at 09:30 patient got her first dose of BNT162B2 at one of their sites. About an hour or two ago, she noticed swelling in the cheek and under the eye and a rash. It was nothing severe. She has a history of a similar allergic reaction. She has an allergy to eggs and a bee sting and also a few drugs that she was sensitive to. She spoke with her physician at NYU and made them aware of all of these before she got it and she felt fine. She stayed 30 minutes. She was a little lightheaded, but she had not eaten or drank anything. She went home, made lunch, and now she sees a little swelling in her cheek and some redness. She still has to get the second shot. She would like to know if she should be concerned about this. The outcome of the events swelling in the cheek and under the eye, swelling in the cheek and under the eye and rash was not recovered and for event little lightheaded was recovering.
She waited until the 28th to go to the doctor because they told her to wait. She had severe headaches and nausea. No tests were required for her systems because they suggested motrin for the minute neuromuscular spasms.
Moderna Covid-19 vaccine that was punctured on Wed 06Oct2021 @ 2p, then placed in refrigerator. It was administered to a patient today.; Interchange of vaccine products administered; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Moderna Covid-19 vaccine that was punctured on Wed 06Oct2021 @ 2p, then placed in refrigerator. It was administered to a patient today.) and INTERCHANGE OF VACCINE PRODUCTS (Interchange of vaccine products administered) in a 47-year-old patient of an unknown gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 014F21A) for COVID-19 vaccination.    Co-suspect product included non-company product TOZINAMERAN (PFIZER BIONTECH COVID-19 VACCINE) for COVID-19 vaccination.    Concurrent medical conditions included Immunocompromised.   On 18-Jan-2021, the patient received first dose of TOZINAMERAN (PFIZER BIONTECH COVID-19 VACCINE) (unknown route) 1 dosage form. On 08-Feb-2021, received second dose of TOZINAMERAN (PFIZER BIONTECH COVID-19 VACCINE) (unknown route) dosage was changed to 1 dosage form. On 08-Oct-2021, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 08-Oct-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (Moderna Covid-19 vaccine that was punctured on Wed 06Oct2021 @ 2p, then placed in refrigerator. It was administered to a patient today.) and INTERCHANGE OF VACCINE PRODUCTS (Interchange of vaccine products administered). On 08-Oct-2021, EXPIRED PRODUCT ADMINISTERED (Moderna Covid-19 vaccine that was punctured on Wed 06Oct2021 @ 2p, then placed in refrigerator. It was administered to a patient today.) and INTERCHANGE OF VACCINE PRODUCTS (Interchange of vaccine products administered) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Concomitant medication was not provided. Treatment information was not provided.  Had bottle of Moderna Covid-19 vaccine that was punctured on Wed 06 Oct 2021.